Directorate-General for Health and Food Safety
Health systems performance assessment
The study aims to analyse the policy options of 'external price referencing' (EPR) and 'differential pricing' (DP) in terms of technical, economic and legal considerations, in order to investigate possible benefits from improved cross-country policy coordination in the area of pharmaceutical pricing.
A probabilistic Markov-Model of age-related disability rates for selected disease causes and related impacts on public payer cash benefit expenditure
This report contains the results of a study carried out under an EU Tender launched by the Consumers, Health and Food Executive Agency within Work Plan 2009 of the Second Programme of Community Action in the Field of Health 2008–2013.
Supplement to the final report (including the template of the Public Health Capacity Assessment Tool used for the analysis and the subsequent summary of scores for each indicator. This document also contains a summary of the case study analysis and the results of the Appreciative Inquiry method.)
External reference pricing of medicinal products: simulation-based considerations for cross-country coordination